Novo Nordisk: STEP Young Phase 3 Trial With Semaglutide Shows Superior BMI Reduction At Week 68

Novo Nordisk announced initial results from the Phase 3 STEP Young trial of once-weekly semaglutide for obesity in children aged 6 to under 12. The study evaluates semaglutide alongside a reduced-calorie diet and increased physical activity, potentially expanding the company’s obesity-treatment opportunity into a younger pediatric population. The provided article text does not include efficacy, safety, or statistical-result details.